Introduction
============

It is a common part of managing the life cycle of a biological drug, as with all medications, to undergo revisions to the manufacturing processes ([@b1-ejr-6-1-23]), all of which are strictly regulated ([@b2-ejr-6-1-23]). Etanercept (ETN) is a dimeric, human recombinant fusion protein that binds specifically to tumor necrosis factor (TNF) and lymphotoxin, inhibiting their interaction with cell surface receptors ([@b3-ejr-6-1-23], [@b4-ejr-6-1-23]). ETN has been manufactured using a number of processes since its approval in 1998, with each change reflecting technological developments to improve process robustness and to ensure product safety and supply. The last major ETN manufacturing change was the introduction of the serum-free process (SFP) (European Medicines Agency/H/C/262/II/83, approved on February 28, 2008) ([@b5-ejr-6-1-23]). The current modifications to the manufacturing process have been made to allow for an increase in the yield of drug substance from the same cell bank used in manufacturing the current ETN. There were no changes to the drug product formulations as a result of the introduction of the new manufacturing process for the drug substance.

Treatment with biological agents, including TNF inhibitors, such as ETN, has proven to be effective by reducing disease activity and improving patient quality of life in those who have not responded well to conventional disease-modifying antirheumatic drugs (DMARDs) ([@b6-ejr-6-1-23]--[@b9-ejr-6-1-23]). TNF inhibitors and other biological agents have an inherent capacity to be immunogenic. Thus, there is a potential to elicit unwanted immune responses, including the development of antidrug antibodies (ADAs), which may raise safety concerns for the patient as well as interfere with drug efficacy ([@b10-ejr-6-1-23]--[@b12-ejr-6-1-23]). Some ADAs do not affect drug activity and are designated as non-neutralizing, whereas other ADAs can become neutralizing antibodies (NAbs) negatively affecting the ability of the biological agent to bind to its target ([@b13-ejr-6-1-23]). Several studies have demonstrated that the presence of ADA in patients with rheumatoid arthritis (RA) treated with TNF inhibitors resulted in subtherapeutic serum drug levels and loss of efficacy, usually referred to as secondary failure ([@b14-ejr-6-1-23]--[@b17-ejr-6-1-23]). The presence of ADA was not linked to reduced clinical response in studies reporting ADA against ETN ([@b15-ejr-6-1-23]--[@b17-ejr-6-1-23]). The presence of ADAs may also contribute to the incidence of adverse events (AEs), such as injection-site and infusion reactions, thromboembolic events, and serum sickness ([@b11-ejr-6-1-23], [@b18-ejr-6-1-23], [@b19-ejr-6-1-23]).

Studies of the current commercially available SFP formulation of ETN reported ADAs in approximately 5% of patients with RA after 24 weeks of treatment, none of which were neutralizing ([@b15-ejr-6-1-23]--[@b17-ejr-6-1-23]). Although ETN produced by the serum-free, high-capacity manufacturing (SFHCM) process has no new structural features and is, therefore, predicted not to have an altered immunogenicity profile compared with the current SFP ETN, the present study was conducted to demonstrate that it is clinically similar to ETN manufactured by the current process so that it may be administered safely and with confidence to the patients. We report on the immunogenicity, safety, and efficacy of ETN manufactured by the SFHCM process administered at the same dose (50 mg once weekly (QW)) as the current commercially available ETN to ETN naïve patients with RA.

Methods
=======

Study design
------------

This was a global, multicenter, open-label, single-arm study (NCT02378506) conducted in 29 centers in nine countries (Bulgaria, Croatia, Germany, Greece, Hungary, Poland, Serbia, Slovakia, and South Africa) from April 2015 to June 2016. The study was conducted in accordance with the Declaration of Helsinki. Ethics committee approvals for this study were received from the relevant regulatory bodies in each country (see [Appendix](#app1-ejr-6-1-23){ref-type="app"} at the last page). Informed consent was obtained from all of the patients who participated in the study.

All eligible patients were screened within 4 weeks prior to the first dose. Patients were administered ETN 50 mg QW subcutaneously for 24 weeks. Immunogenicity (ADAs and NAbs) was measured at baseline and subsequent visits at 12 and 24 weeks. The efficacy, safety, and patient-reported outcomes were measured at baseline and subsequent visits at 4, 12, and 24 weeks. A safety follow-up was conducted via telephone 28--32 days after 24 weeks or early withdrawal visit.

Patients
--------

Adult patients with active moderate to severe RA (disease activity score based on 28 joint count (DAS28) ≥3.2, tender joint count (TJC) ≥4, and swollen joint count (SJC) ≥4) at screening and baseline visits, who had not been treated previously with ETN, and with normal laboratory results were enrolled in the study. Patients who were previously treated with ETN, received methotrexate \>25 mg/week or had a change in dose or route of administration of methotrexate within 6 weeks of the first study dose, had a dose change in permitted conventional synthetic DMARDs within 4 weeks of the first study dose, received cyclophosphamide, cyclosporine, or azathioprine within 6 months of the first study dose, received TNF inhibitor or any other biological treatment for RA within 12 weeks of the first study dose, received any biological B cell-depleting agent (e.g., rituximab) within 2 years of the first study dose, received corticosteroids within 4 weeks of the first study dose, received nonsteroidal anti-inflammatory drugs more than the maximum recommended dose, or received live (attenuated) vaccines within 4 weeks of the first study dose were excluded from the study. Patients with serious infections within 4 weeks, with active infections at the time of screening or baseline visits, with active or latent tuberculosis, or with any medical condition that could interfere with the assessments were also excluded.

Assessments
-----------

ETN concentration was measured from serum samples collected prior to the first dose and after 12 and 24 weeks of treatment or upon early withdrawal, using a validated enzyme-linked immunosorbent assay (ELISA). Serum samples used to test for ADAs to ETN were collected simultaneously in order to minimize the potential drug effect and were assayed using the same validated ELISA used throughout the development of ETN. During the most recent cross-validation, the assay precision for the negative control, expressed as the between-day percent coefficient of variation, was 20.2%.

Samples were deemed positive if the optical density was two times than what was observed in the pre-treatment samples. There was no distinction between the positive samples of different titers. All samples testing positive for ADA were subsequently evaluated for the presence of Nabs using a validated ELISA. During the most recent cross-validation, the assay precision for the negative control was ≤13.3%. All assays were conducted by Celerion (formerly MDS Pharma Services, Lincoln, NE, USA).

The incidence and severity of all AEs and serious AEs (SAEs) were recorded, and the abnormal test findings, laboratory evaluations, and vital signs were monitored. The efficacy of treatment was determined as 20%, 50%, and 70% improvements from baseline in the American College of Rheumatology (ACR) criteria for RA (ACR20, ACR50, and ACR70, respectively), DAS28 by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), number of TJC and SJC, Physician Global Assessment (PGA), Patient Global Assessment (PtGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), patient general health, and patient pain assessed using a Visual Analog Scale (VAS).

Statistical analysis
--------------------

Approximately 180 patients were enrolled to provide 162 evaluable patients. Assuming that the true incidence of ETN ADA formation was ≤5%, the probability of obtaining an estimate of \>10% was not \>0.33%. If the true incidence of ETN ADA formation was ≥10%, the probability of obtaining an estimate of ≤5% was not \>1.54%. This number of patients would also provide 80% probability of observing one or more safety events with an incidence of ≥1%. Events and response proportions are presented as percentages (%) with 95% confidence intervals. For composite endpoints, including the DAS28-CRP and ACR responses, missing values of component parameters were carried forward from the previous visit. There was no formal statistical testing planned. A life-table estimate of the cumulative incidence of antibody formation through 12 and 24 weeks was performed to adjust the estimate for incomplete data. The life-table analysis accounted for when subjects completed the ADA evaluations and whether subjects discontinued the study early, prior to the protocol-specified 24 weeks of the study duration of treatment.

Results
=======

Patients
--------

A total of 188 patients were enrolled in the study. Of the patients, 163 (86.7%) completed the study ([Figure 1](#f1-ejr-6-1-23){ref-type="fig"}). One patient withdrew consent prior to any drug administration. An additional 22 patients discontinued during the study, with 3 (1.6%) for lack of efficacy, 14 (7.4%) due to AEs, 2 (1.1%) for protocol deviation, 1 (0.5%) died, 4 (2.1%) for withdrawal of consent, and 1 (0.5%) for other reasons. The baseline patient characteristics ([Table 1](#t1-ejr-6-1-23){ref-type="table"}) were similar to published patient characteristics for studies demonstrating ETN efficacy and safety in patients with RA ([@b6-ejr-6-1-23]--[@b9-ejr-6-1-23]). Overall, 153 (81.8%) patients received concomitant methotrexate during the study.

Immunogenicity
--------------

The median duration of treatment was 23 (21.6±5.0) weeks. Data on the ADA status during the course of the study were missing for 11 patients, with 10 due to mishandling of the baseline sample and 1 withdrew consent at 4 weeks. The baseline patient characteristics for patients testing positive for ADA are comparable to those testing negative ([Table 1](#t1-ejr-6-1-23){ref-type="table"}). Of the 176 patients for whom immunogenicity data were available (at least one ADA assessment), 8 (4.5%) tested positive for ADA at any time throughout the study ([Table 2](#t2-ejr-6-1-23){ref-type="table"}), all of whom were receiving concomitant methotrexate. Of these 8 patients, 3 (1.7%) tested positive at 12 weeks (individual ADA titers of 200, 400, and 400 arbitrary units (AU)/mL), and 5 (2.8%) more tested positive at 24 weeks or early termination (individual ADA titers of 100, 200, 400, 400, and \>400 ADA AU/mL). High and low ADA titers were not distinguished, as all positive samples were subsequently tested, and all were found to be negative for NAbs. Since early termination can occur at any time during the study, some patients tested positive for ADA prior to 12 weeks. The cumulative incidence rates were 3.64% up to 12 weeks and 6.16% up to 24 weeks using a life-table analysis.

The mean±standard deviation (SD) concentrations of ETN at 12 weeks were 1.5±0.2 μg/mL among patients testing positive for ADA (n=3) and 2.3±1.3 μg/mL among those testing negative for ADA (n=154; p=0.29). At 24 weeks or early termination, the mean±SD concentrations were 1.0±0.5 μg/mL (n=5) and 2.3±1.7 μg/mL (n=158; p=0.02), respectively.

Safety
------

[Table 3](#t3-ejr-6-1-23){ref-type="table"} summarizes all-cause treatment-emergent AEs (TEAEs). A total of 90 (48.1%) patients reported 196 TEAEs, 27 (14.4%) patients reported 48 injection-site reactions, 43 (23.0%) patients reported 50 investigator-identified infections, and 56 (29.9%) patients reported 98 other AEs. Nine (4.8%) patients reported 11 SAEs, with lymphadenopathy, acute cardiac failure, metatarsalgia, osteoarthritis, major depression, ureteric calculus, urticaria, deep vein thrombosis, diverticulitis, pneumonia, and wound infection for each. Six (3.2%) patients reported severe AEs, with urticaria, lymphadenopathy, acute cardiac failure, retinal detachment, back pain, and allergic dermatitis for each. Fourteen (7.5%) patients experienced an AE leading to discontinuation, with three due to injection-site reactions, two due to infections, and one each due to urticaria, lymphadenopathy, acute cardiac failure, macular rash, depression, allergic dermatitis, pruritic rash, thrombocytopenia, and one worsening of RA, and one death was due to acute heart failure. Fifty-two (27.8%) patients experienced an AE considered by the investigator to be drug-related. There were no TEAEs of opportunistic infections, malignancies, demyelinating disorders, or prespecified events of clinical importance reported. The majority of AEs were mild or moderate in severity.

Efficacy
--------

Overall, the proportions of patients achieving ACR20, ACR50, and ACR70 increased progressively over time ([Figure 2a](#f2-ejr-6-1-23){ref-type="fig"}), accompanied by a decrease in DAS28-ESR and DAS28-CRP scores ([Figure 2b](#f2-ejr-6-1-23){ref-type="fig"}) and an increase in the proportion of patients achieving low disease activity (LDA; \<3.2) and remission (\<2.6) according to both DAS28-ESR and DAS28-CRP criteria (data not shown). At 24 weeks, 44.4% (72/162) and 66.0% (107/162) of patients achieved LDA, as measured via DAS28-ESR and DAS28-CRP, respectively, and 29.6% (48/162) and 48.1% (78/162) achieved disease remission ([Figure 2c](#f2-ejr-6-1-23){ref-type="fig"}).

When analyzed by the ADA status, a progressive increase in ACR20 and ACR50 responses was observed over time for patients testing positive and negative for ADA ([Figure 3a](#f3-ejr-6-1-23){ref-type="fig"}). However, there was no patient testing positive for ADA who achieved an ACR70 response at any time point ([Figure 3a](#f3-ejr-6-1-23){ref-type="fig"}). DAS28-ESR and DAS28-CRP scores decreased progressively over time in both patients testing positive and negative for ADA ([Figure 3b](#f3-ejr-6-1-23){ref-type="fig"}). At 24 weeks, 50.0% (2/4) of patients testing positive for ADA achieved LDA, as measured via DAS28-ESR and DAS28-CRP, compared with 44.3% (66/149) and 67.1% (100/149) of patients testing negative for ADA, respectively ([Figure 3c](#f3-ejr-6-1-23){ref-type="fig"}). Furthermore, 25.0% (1/4) and 50.0% (2/4) of patients testing positive for ADA achieved disease remission, as measured via DAS28-ESR and DAS28-CRP, respectively, compared with 30.2% (45/149) and 49.7% (74/149) of patients testing negative for ADA ([Figure 3c](#f3-ejr-6-1-23){ref-type="fig"}).

Over the course of the study, there were consistent decreases in TJC and SJC, as well as decreases in scores for PGA, PtGA, HAQ-DI, patient's assessment of general health, and pain VAS ([Figure 4](#f4-ejr-6-1-23){ref-type="fig"}).

Discussion
==========

The present study assessed the immunogenicity, safety, and efficacy of ETN manufactured using the SFHCM process in 187 subjects with moderate to severe RA during 24 weeks of administration. We compared the immunogenicity, safety, and efficacy of ETN manufactured by the SFHCM process with historical results. The current commercially available ETN induces a significantly lower immunogenic response, with the development of fewer ADAs, than anti-TNF monoclonal antibodies ([@b20-ejr-6-1-23]). Furthermore, treatment with the current commercial formulation of ETN has not been associated with the development of detectable NAbs ([@b7-ejr-6-1-23], [@b16-ejr-6-1-23]).

The incidence of 8 (4.5%) patients developing ADA is consistent with findings for ETN manufactured using the current manufacturing process, which report up to 5% of patients developing ADA ([@b7-ejr-6-1-23], [@b21-ejr-6-1-23]). It is not surprising that all eight patients were receiving concomitant methotrexate, since \>81% of patients were in this group. Importantly, from a clinical efficacy point of view, none of the patients treated in the present study developed NAbs. In addition, importantly, the ETN used in the present study was well tolerated, with most of the AEs being mild or moderate in severity. These data are also consistent with published studies ([@b7-ejr-6-1-23], [@b11-ejr-6-1-23], [@b14-ejr-6-1-23]--[@b17-ejr-6-1-23]). These results confirmed that ETN manufactured by the SFHCM process retained low immunogenicity potential and a favorable risk-to-benefit ratio when compared with the current commercially available ETN.

The efficacy of ETN manufactured using the SFHCM process, shown as improvements in ACR response, DAS28 score, and other efficacy parameters, was similar to that observed in controlled clinical trials with similar enrollment criteria ([@b6-ejr-6-1-23]--[@b9-ejr-6-1-23]). However, the presence of ADAs appeared to reduce the therapeutic response to ETN as measured by ACR, as no patients who developed ADAs achieved an ACR70 response at any time point, unlike the patients who did not develop ADAs. There were no significant differences in decreased disease activity, as measured using DAS28, between patients who developed ADAs and those who did not. However, it is important to note that no formal efficacy comparisons were planned or performed between patients with and without ADAs due to the small number of patients who were expected to develop ADAs after treatment with ETN that was manufactured using the SFHCM process. Consistent with published studies, ETN manufactured in this SFHCM process was well tolerated ([@b6-ejr-6-1-23]--[@b9-ejr-6-1-23]). Our study was conducted in a population of patients with characteristics that have been well established for the evaluation of new biological agents for the treatment of RA, including a relatively low proportion (15.5%) of patients exposed to prior biological DMARDs and a high proportion of patients receiving concomitant glucocorticoids (51.9%) and methotrexate (90.4%). In addition, the single-arm, open-label study design must be taken into consideration when interpreting the efficacy results. Finally, although the ELISA methodology used to measure ETN levels and ADA/NAb titers is widely used and recognized as reliable, it does have some limitations, including non-specific binding and failure to detect low-affinity antibodies ([@b22-ejr-6-1-23]). However, we believe that the comparison of ETN concentrations and ADA frequency results from the present study with those from previous ETN studies is justified because the same ELISA methodology has been used throughout the development of ETN.

When compared with historical data on the current commercially available ETN, this single-arm, open-label study with ETN manufactured using the SFHCM process has succeeded in meeting all the objectives pertaining to immunogenicity, safety, and efficacy. Changes in the manufacturing processes are needed to take advantage of new technologies and to maintain adequate supplies of medications for patients. Strictly regulated revision of changes in the manufacturing process of ETN, as with other therapeutic agents, is a common part of the ongoing aim to keep an established medicine safe and efficacious while improving manufacturing. This is important for clinical consistency so that both physicians and patients can be confident about the reproducibility and reliability of the safety and efficacy results when prescribing or receiving ETN manufactured via a new process.
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![Clinical responses\
Proportions of patients achieving ACR20, ACR50, and ACR70 (b); DAS28-ESR and DAS28-CRP scores (b); proportions of patients achieving LDA and remission according to the DAS28-ESR and DAS28-CRP criteria at 24 weeks (c). For composite measures, missing component values were imputed using the last observation carried forward\
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![Clinical responses by the ADA status\
Proportions of ADA+ and ADA− patients achieving ACR20, ACR50, and ACR70 (a); DAS28-ESR and DAS28-CRP scores in ADA+ and ADA− patients (b); proportions of ADA+ and ADA− patients achieving LDA and remission according to the DAS28-ESR and DAS28-CRP criteria at 24 weeks (c). For composite measures, missing component values were imputed using the last observation carried forward\
ACR20; ACR50; ACR70: American College of Rheumatology criteria for RA, ADA: antidrug antibody, CRP: C-reactive protein, DAS28: disease activity score based on 28 joint count, ESR: erythrocyte sedimentation rate, LDA: low disease activity, SD: standard deviation](EJR-6-1-23-g03){#f3-ejr-6-1-23}

![Summary of efficacy assessments at 24 weeks\
HAQ-DI: Health Assessment Questionnaire-Disability Index, PGA: Physician Global Assessment, PtGA: Patient Global Assessment, SD: standard deviation, SJC: swollen joint count, TJC: tender joint count, VAS: Visual Analog Scale](EJR-6-1-23-g04){#f4-ejr-6-1-23}

###### 

Baseline patient characteristics by ADA status[\*](#tfn1-ejr-6-1-23){ref-type="table-fn"}

                             Total (n=187)[\*\*](#tfn2-ejr-6-1-23){ref-type="table-fn"}   ADA+(n=8)     ADA-(n=168)
  -------------------------- ------------------------------------------------------------ ------------- -------------
  Age (years)                54.2 (12.9)                                                  58.8 (15.0)   54.2 (12.5)
  Female, n (%)              159 (85.0)                                                   6 (75.0)      145 (86.3)
  Race, n (%)                                                                                           
  White                      179 (95.7)                                                   8 (100.0)     160 (95.2)
  Black                      0 (0.0)                                                      0 (0.0)       0 (0.0)
  Asian                      4 (2.1)                                                      0 (0.0)       4 (2.4)
  Other                      4 (2.1)                                                      0 (0.0)       4 (2.4)
  Baseline BMI (kg/m2)       27.3 (5.2)                                                   27.2 (6.2)    27.5 (5.3)
  Disease duration (years)   8.0 (7.2)                                                    10.3 (13.0)   7.8 (7.0)
  Prior medications, n (%)                                                                              
  Non-biological DMARDs      96 (51.3)                                                    2 (25.0)      87 (51.8)
  Biological DMARDs          29 (15.5)                                                    3 (37.5)      26 (15.5)
  Corticosteroids            97 (51.9)                                                    0 (0.0)       89 (53.0)
  Methotrexate               169 (90.4)                                                   8 (100.0)     152 (90.5)
  RF positive, n (%)         116 (62.0)                                                   3 (37.5)      108 (64.3)
  Anti-CCP positive, n (%)   126 (67.4)                                                   3 (37.5)      117 (69.6)
  ESR (mm/h)                 36.1 (22.1)                                                  36.0 (26.4)   34.9 (21.6)
  CRP (mg/L)                 11.2 (16.0)                                                  17.2 (22.1)   10.6 (14.9)
  TJC                        14.2 (6.0)                                                   16.0 (6.3)    13.9 (6.1)
  SJC                        10.9 (5.2)                                                   13.2 (7.1)    10.6 (5.1)
  DAS28-ESR                  6.2 (0.9)                                                    6.5 (0.9)     6.1 (0.9)
  DAS28-CRP                  5.4 (0.9)                                                    5.9 (1.0)     5.3 (0.9)

Data were presented as mean (SD), unless otherwise stated

The total numbers do not add up to the other two columns because the ADA data for 11 patients were not available ADA: antidrug antibody, BMI: body mass index, CCP: cyclic citrullinated peptide, CRP: C-reactive protein, DAS28: disease activity score based on 28 joint count, DMARD: disease-modifying antirheumatic drug, ESR: erythrocyte sedimentation rate, RF: rheumatoid factor, SD: standard deviation, SJC: swollen joint count, TJC: tender joint count

###### 

Summary of the incidence of patients developing ADA against ETN by methotrexate treatment status[\*](#tfn3-ejr-6-1-23){ref-type="table-fn"}

                                     All patients (n=176)   No methotrexate (n=16)   Methotrexate (n=160)
  ---------------------------------- ---------------------- ------------------------ ----------------------
  Total                              4.5 (2.2--8.4)         0.0 (0.0--14.3)          5.0 (2.4--9.2)
  At 12 weeks                        1.9 (0.5--5.0)         0.0 (0.0--16.2)          2.1 (0.6--5.5)
  At 24 weeks or early termination   2.9 (1.1--6.1)         0.0 (0.0--14.3)          3.1 (1.2--6.8)
  At any time                        4.5 (2.2--8.4)         0.0 (0.0--14.3)          5.0 (2.4--9.2)

Data were presented as percentage (%, 95% CI)

ADA: antidrug antibody, CI: confidence interval, ETN: etanercept

###### 

Total

                                                       Total       Injection-site reactions   Infections   All other
  ---------------------------------------------------- ----------- -------------------------- ------------ -----------
  Total no. of AEs                                     196         48                         50           98
  Patients with AEs                                    90 (48.1)   27 (14.4)                  43 (23.0)    56 (29.9)
  Patients with SAEs                                   9 (4.8)     0 (0.0)                    3 (1.6)      8 (4.3)
  Patients with severe AEs                             6 (3.2)     0 (0.0)                    0 (0.0)      6 (3.2)
  Patients discontinuing due to AEs                    14 (7.5)    3 (1.6)                    2 (1.1)      9 (4.8)
  Patients with temporary discontinuation due to AEs   21 (11.2)   0 (0.0)                    18 (9.6)     5 (2.7)

Data were presented as n (%)

AE: adverse event, SAE: serious adverse event, TEAE: treatment-emergent adverse event
